Document:

exv10w9

Exhibit 10.9

LIMITED LICENSE AGREEMENT

This Limited License Agreement (this “Agreement”), effective the 10th day of June, 2009 (the
“Effective Date”), is by and between Sorrento Therapeutics, Inc., a California corporation (“STI”),
having its principal place of business at San Diego, California, U.S.A. and OPKO Health, Inc., a
Delaware corporation (“OPKO”), having its principal place of business at Miami, Florida, U.S.A. As
used herein, each of OPKO and STI are referred to individually as a “Party” and collectively as the
“Parties”.

Recitals

WHEREAS, OPKO is purchasing a certain number of shares of STI’s stock pursuant to a stock purchase
agreement entered into concurrently with this Agreement (the
“Stock Purchase Agreement”);

WHEREAS, STI owns certain patent rights relating to the manufacture of human antibody libraries;

WHEREAS, OPKO is desirous of acquiring an exclusive license under such patent rights for the
development, manufacture, use, sale, offer for sale, import and export of certain products within
the OPKO Field (as defined below); and

WHEREAS, STI is willing to grant OPKO such an exclusive license in the OPKO Field in accordance
with the terms and conditions set forth in this Agreement;

NOW, THEREFORE, in consideration of mutual covenants and conditions set forth herein and the Stock
Purchase Agreement and other good and valuable consideration the adequacy, sufficiency and receipt
of which is hereby acknowledged by the Parties, STI and OPKO hereby agree as follows:

Agreement

Article 1 - Definitions

	1.1	 	Affiliate. The term “Affiliate” shall mean any corporation, company, partnership,
joint venture and/or firm which controls, is controlled by, or is under common control with a
Party. For purposes hereof, “control” shall mean (a) in the case of corporate entities, direct
or indirect ownership of at least fifty percent (50%) of the stock or shares having the right
to vote for the election of directors, and (b) in the case of non-corporate entities, direct
or indirect ownership of at least fifty percent (50%) of the equity interest with the power to
direct the management and policies of such non-corporate entities.
	 
	1.2	 	Licensed Library. The term “Licensed Library” shall mean any population of distinct
molecules, including but not limited to, peptides, polypeptides, proteins or polynucleotides,
the manufacture, use, sale, or importation of which is covered by any claim of the STI Patents
or which is derived by use of any process or method covered by any claim of the STI Patents.
	 
	1.3	 	OPKO Field. The term “OPKO Field” shall mean development, manufacture, marketing,
and sale of drugs for ophthalmological indications.

Page 1

 

	1.4	 	OPKO Patent. The term “OPKO Patent” shall mean any patent or patent application (i)
owned or controlled by OPKO or any of its Affiliates, including any patent application filed
by or on behalf of OPKO or any of its Affiliates, and (ii) which has at least one claim that
covers any use, manufacture, sale, offer for sale, or importation of a Selected Product, such
as any patent or patent application directed to the composition of matter for a Selected
Product.
	 
	1.5	 	Selected Product. The term “Selected Product” shall mean any molecule, including but
not limited to any peptide, polypeptide, protein or polynucleotide, which is identified and
selected through the use of a Licensed Library.
	 
	1.6	 	STI Field. The term “STI Field” shall mean any field of use, other than the OPKO
Field.
	 
	1.7	 	STI Patents. The term “STI Patents” shall mean all United States and foreign patents
and patent applications owned or controlled by STI or its Affiliate at any time during the
term of this Agreement, which has at least one claim that covers (i) any use, manufacture,
sale, offer for sale, or importation of a Selected Product, such as any patent or patent
application directed to the composition of matter for a Selected Product, or (ii) the
manufacture or creation of the Licensed Library, including but not limited to, a) U.S. Patent
Number 7,405,062, entitled “Method for cloning variable domain sequences of immunological gene
repertoire”, all other patents and patent applications listed in Exhibit A and all
corresponding or related inventor certificates, (b) any and all continuations,
continuations-in-part, continuing prosecution applications, and divisionals based on any
patent or patent application referenced herein, (c) any and all patents issuing from any
applications referenced herein, (d) any reissues, renewals, reexaminations and extensions
based on any patents referenced herein, and (e) all corresponding foreign counterparts and
foreign patent applications and issued patents in any country throughout the world.
	 
	1.8	 	 Territory.  The term “Territory” shall mean worldwide.

Article 2
- License Grant

	2.1	 	Exclusive License for Selected Products. Subject to the terms and conditions of this
Agreement, STI hereby grants to OPKO an exclusive, royalty-free, fully-paid, worldwide,
non-transferable (except as permitted under Section 9.1) right and license, under the STI
Patents: (i) to develop, use, make and have made Selected Products within the OPKO Field and
in the Territory; and (ii) to market, promote, sell, offer to sell, transfer, distribute,
import and export Selected Products within the OPKO Field and in the Territory.
	 
	2.2	 	Exclusive License for Licensed Library. To the extent STI provides to OPKO the
Licensed Library pursuant to Section 3.1, subject to the terms and conditions of this
Agreement, STI hereby grants to OPKO an exclusive, royalty-free, fully-paid, worldwide,
non-transferable (except as permitted under Section 9.1) right and license, under the STI
Patents, to use and screen the Licensed Library to identify, select and commercialize one or
more Selected Products within the OPKO Field and in the Territory.

Page 2

 

	2.3	 	Sublicensing Right. OPKO will have the right to sublicense any of the rights granted
under Sections 2.1 and 2.2, provided that OPKO enters into a sublicense agreement with the
sublicensee in writing and the sublicense agreement (i) conforms in all respects to the
applicable terms and conditions of this Agreement, including all restrictions and limitations
provided herein, (ii) specifies that such sublicense does not include any rights outside the
OPKO Field, and (iii) includes a covenant by the sublicensee not to practice the STI Patents
outside the OPKO Field.
	 
	2.4	 	Reservation of Rights. STI reserves all rights in the STI Patents outside the OPKO
Field and not expressly granted under Sections 2.1 and 2.2, provided that in any license,
transfer or other assignment of rights under the STI Patents to a third party, STI shall
specify that such license, transfer or assignment of rights under the STI Patents does not
include any rights to a Selected Product in the OPKO Field. STI shall also use commercially
reasonable efforts to negotiate a covenant from such third party that such third party will
not enforce any patent claim that is directed to a composition of matter against OPKO within
the OPKO Field (“Covenant Not to Sue”), provided that a failure by STI to obtain such Covenant
Not to Sue despite using its commercially reasonable efforts shall not be considered a breach
of this Agreement by STI. OPKO will not practice the STI Patents outside the scope of the
licenses granted in Sections 2.1 and 2.2. Specifically, the licenses granted under Sections
2.1 and 2.2 do not include the right to manufacture or have manufactured the Licensed Library
under the STI Patents.

Article 3 - Access to Licensed Library

	3.1	 	Licensed Library. Upon reasonable request of OPKO, STI will provide OPKO with access
to the Licensed Library. After OPKO has identified a target, STI will either (i) provide an
aliquot of the Licensed Library based on the identified target, or (ii) screen the Licensed
Library based on the identified target on behalf of the OPKO. In consideration for performing
these services, OPKO will pay STI reasonable, industry standard fees, to be mutually agreed to
by the Parties. STI may utilize a third party contractor reasonably acceptable to OPKO to
perform its obligations under this Section 3.1.
	 
	3.2	 	Material Transfer Agreement. To the extent STI elects to provide an aliquot of the
Licensed Library as describe in Section 3.1, the Parties will enter into an industry standard
material transfer agreement for the transfer of Licensed Library from STI to OPKO, and OPKO
may use the transferred Licensed Library solely as provided in Section 2.2. In addition, OPKO
will promptly notify STI in writing, (i) which targets were screened using the Licensed
Library, and (ii) the identity of the Selected Products identified and selected based on such
screening.

Article 4 -  Grant Back of OPKO Patents and Prosecution.

	4.1	 	Grant Back to STI. OPKO hereby grants to STI an exclusive, royalty-free, fully-paid,
worldwide, non-transferable (except as permitted under Section 9.1) right and license, under
the OPKO Patents: (i) to develop, use, make and have made Selected Products in the STI Field
and in the Territory; and (ii) to market, promote, sell, offer to sell, transfer, distribute,
import and export Selected Products in STI Field and in the Territory. OPKO

Page 3

 

	 	 	specifically reserves all rights in the OPKO Patents and STI Patents in the OPKO Field, and
STI will not practice the OPKO Patents or STI Patents outside the STI Field.

	4.2	 	STI will have the right to sublicense any of the rights granted under this Section, provided
that STI enters into a sublicense agreement with the sublicensee in writing and the sublicense
agreement (i) conforms in all respects to the applicable terms and conditions of this
Agreement, including all restrictions and limitations provided herein, (ii) specifies that
such sublicense does not include any rights outside the STI Field, and (iii) includes a
covenant by the sublicensee not to practice the STI Patents outside the STI Field.
	 
	4.3	 	Notice of OPKO Patent. Prior to filing any OPKO Patent or promptly after acquiring
ownership or exclusive license rights in any OPKO Patent, OPKO will notify STI in writing and
provide a copy of the applicable draft application, pending application, or issued patent.
	 
	4.4	 	Notice of STI Patent. Prior to filing any STI Patent or promptly after acquiring
ownership or exclusive license rights in any STI Patent, STI will notify OPKO in writing and
provide a copy of the applicable draft application, pending application, or issued patent.
	 
	4.5	 	Prosecution of STI Patent. As between the Parties, STI will be responsible for and
will control the filing, prosecution and maintenance of the STI Patents, including all fees
and costs relating thereto. STI will notify OPKO periodically of the status of any pending
cases included in the STI Patents, and will provide OPKO with copies of any office actions,
notices of allowance, and other material documents filed with or received from any patent
office concerning the STI Patents. OPKO will have the opportunity to comment on any response
to office actions for STI Patents or amendments to claims in STI Patents related to the OPKO
Field prior to their filing and STI will consider and accommodate all comments from OPKO in
good faith, including filing any divisional, continuation, or continuation-in-part application
to include claims that are directed to OPKO Field, provided that OPKO shall be solely
responsible for any patent expenses or costs related to the OPKO Field. Any differences
between the Parties with respect to any STI Patent prosecution matters will be discussed and
the Parties will use good faith efforts to resolve such differences to their mutual
satisfaction. If STI decides not to continue the prosecution of any pending case or not to
maintain any issued patent included in the STI Patents, STI will promptly notify OPKO in
writing at least thirty (30) days before the pending case is abandoned or the issued patent is
lapsed. If OPKO desires to take over the prosecution of the pending case or the maintenance
of the issued patent, OPKO will notify STI of such desire and will have the right to prosecute
such pending case or to maintenance such issued patent in the name of and on behalf of OPKO.
	 
	4.6	 	Prosecution of OPKO Patent. As between the Parties, OPKO will be responsible for and
will control the filing, prosecution, and maintenance of the OPKO Patents, including all fees
and costs relating thereto. OPKO will notify STI periodically of the status of any pending
cases included in the OPKO Patents, and will provide STI with copies of any

Page 4

 

office actions, notices of allowance, and other material documents filed with or received
from any patent office concerning the OPKO Patents. STI will have the opportunity to
comment on any response to office actions for OPKO Patents or amendments to claims in OPKO
Patents relating to the STI Field prior to their filing and OPKO will consider and
accommodate all comments from STI in good faith, including filing any divisional,
continuation, or continuation-in-part application to include claims that are directed to
STI Field, provided that STI shall be solely responsible for any patent expenses or costs
related to the STI Field. Any differences between the Parties with respect to any OPKO
Patent prosecution matters will be discussed and the Parties will use good faith efforts to
resolve such differences to their mutual satisfaction. If OPKO decides not to continue the
prosecution of any pending case or not to maintain any issued patent included in the OPKO
Patents, OPKO will promptly notify STI in writing at least thirty (30) days before the
pending case is abandoned or the issued patent is lapsed. If STI desires to take over the
prosecution of the pending case or the maintenance of the issued patent, STI will notify
OPKO of such desire and will have the right to prosecute such pending case or to
maintenance such issued patent in the name of and on behalf of STI.

Article 5
- Representations and Warranties

	5.1	 	Warranty of Ownership.

5.1.1 STI hereby represents and warrants to OPKO, that:

(a) STI is the sole and exclusive owner of all right, title and interest in and to the
patents licensed by STI hereunder which are free and clear of any liens, pledges, claim,
security interests, rights of first refusal, community property interest or other
restriction or limitation, and any other encumbrances (collectively, “Encumbrances”);

(b) STI has the full right and power to grant the limited exclusive licenses set forth in
this Agreement and there are no outstanding agreements, assignments or Encumbrances which
would prevent STI from granting the licenses granted to OPKO in this Agreement or from
performing STI’s obligations under this Agreement; and

(c) STI is not a party to any agreement or contract that is inconsistent with the exclusive
licenses granted under this Agreement.

	5.2	 	Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN SECTION 5.1, THE PATENTS LICENSED
HEREUNDER ARE PROVIDED “AS IS” AND NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY
WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE PATENTS
LICENSED HEREUNDER, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR
A PARTICULAR PURPOSE, VALIDITY OR ENFORCEABILITY OF THE PATENTS LICENSED HEREUNDER, OR
NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

Page 5

 

Article
6 -  Extension and Enforcement of Patent Rights

	6.1	 	Notice of Patent Infringement by Third Parties. In the event that either Party
becomes aware of any infringement of any patent included in the STI Patents or OPKO Patents
by a third party, such Party shall notify the other Party thereof in writing and shall provide
the other Party with all evidence of such infringement and the basis of such Party’s belief
that such infringement is and/or might have occurred or is occurring.
	 
	6.2	 	OPKO’s Right to Suit. OPKO shall have the sole right, but not the obligation, to
commence in OPKO’s name suits, actions, and proceedings for patent infringement of the STI
Patents or the OPKO Patents by any third party, if the infringement occurs during the term of
this Agreement and within the OPKO Field. Such right shall include without limitation the
right to control the initiation and filing of such actions, suits and proceedings, the
preparation of all papers to be filed in connection therewith and conducting the actions,
suits and proceeding against such third parties. All recoveries, damages, settlement amounts
and awards in such suit, action or proceeding shall be awarded to OPKO. OPKO shall bear all
costs associated with any such suits, actions and proceedings. Upon OPKO’s reasonable
request, STI agrees to assist and cooperate with OPKO in all such actions, suits and
proceedings instituted hereunder, including without limitation being named or joined as a
party thereto if STI is a necessary and indispensable party. OPKO shall pay for all expenses
that STI reasonably incurs in association with such cooperation and assistance. Except as
expressly provided in this Section 6.2, STI reserves all rights to enforce the patents
licensed to OPKO.
	 
	6.3	 	STI’s Right to Suit. STI shall have the sole right, but not the obligation, to
commence in STI’s name suits, actions, and proceedings for patent infringement of the OPKO
Patents or the STI Patents by any third party, if the infringement occurs during the term of
this Agreement and within the STI Field. Such right shall include without limitation the
right to control the initiation and filing of such actions, suits and proceedings, the
preparation of all papers to be filed in connection therewith and conducting the actions,
suits and proceeding against such third parties. All recoveries, damages, settlement amounts
and awards in such suit, action or proceeding shall be awarded to STI. STI shall bear all
costs associated with any such suits, actions and proceedings. Upon STI’s reasonable request,
OPKO agrees to assist and cooperate with STI in all such actions, suits and proceedings
instituted hereunder, including without limitation being named or joined as a party thereto if
OPKO is a necessary and indispensable party. STI shall pay for all expenses that OPKO
reasonably incurs in association with such cooperation and assistance. Except as expressly
provided in this Section 6.3, OPKO reserves all rights to enforce the patents licensed to STI.
	 
	6.4	 	Patent Marking. OPKO will mark all Selected Products within the OPKO Field that are
manufactured or sold under this Agreement with the patent number of each issued patent of the
STI Patents that covers the Selected Products or any process from which the Selected Products
are derived. STI will mark all Selected Products within the STI Field that are manufactured
or sold under this Agreement with the patent number of each issued patent of the OPKO Patents
that covers the Selected Products.

Page 6

 

Article 7
- Term and Termination

	7.1	 	Term. Unless terminated earlier in accordance with this Agreement, the term of this
Agreement and the term of the licenses granted hereunder shall begin on the effective date of
this Agreement and continue until the expiration of the last-to-expire patent within the STI
Patents and the OPKO Patents on a country-by-country basis.
	 
	7.2	 	Termination Upon Default. STI shall have the right to terminate the license granted
under this Agreement to OPKO for cause upon written notice to OPKO if OPKO materially breaches
any provision of this Agreement, and does not cure such breach within thirty (30) days
following written notice thereof from STI. OPKO shall have the right to terminate the license
granted under this Agreement to STI for cause upon written notice to STI if STI materially
breaches any provision of this Agreement, and does not cure such breach within thirty (30)
days following written notice thereof from OPKO.
	 
	7.3	 	Effect Upon Termination. On the effective date of termination of the license
provided to OPKO, OPKO will cease all further use, manufacture, sale, or importation of the
Selected Products within the OPKO Field and all use of the Licensed Library, except as
provided in this Section. OPKO may complete and sell any inventory of the Selected Products
within the OPKO Field that exist as of the termination date for a period of six (6) months
after the termination date. On the effective date of termination of the license provided to
STI, STI will cease all further use, manufacture, sale, or importation of the Selected
Products covered by the OPKO Patents within the STI Field, except as provided in this Section.
STI may complete and sell any inventory of such Selected Products within the STI Field that
exist as of the termination date for a period of six (6) months after the termination date
	 
	7.4	 	Survival. Articles 5, 6, 7, 8, 9, 10, and 11 will survive any termination or
expiration of this Agreement. Upon termination of any license granted to either Party, the
license granted by such Party to the other Party will survive pursuant to the terms of this
Agreement.

Article 8
- Indemnification

	8.1	 	Indemnification by OPKO. OPKO will defend, indemnify and hold STI, STI’s Affiliates,
and their directors, officers, employees, and agents harmless from and against any and all
claims, losses, liabilities, damages, costs, and expenses (including reasonable attorneys’
fees, expert witness fees, and court costs) directly or indirectly arising from or relating to
any activities of OPKO or its sublicensee pursuant to the rights granted hereunder, including
the manufacture, use, marketing, or sale of any Selected Product within the OPKO Field.
	 
	8.2	 	Indemnification by STI. STI will defend, indemnify and hold OPKO, OPKO’s Affiliates,
and their directors, officers, employees, and agents harmless from and against any and all
claims, losses, liabilities, damages, costs, and expenses (including reasonable attorneys’
fees, expert witness fees, and court costs) directly or indirectly arising from or relating to

Page 7

 

any activities of STI or its sublicensee pursuant
to the rights granted hereunder, including the
manufacture, use, marketing, or sale of any
Selected Product within the STI Field.

Article 9
- Assignment; Successors

	9.1	 	Assignment. Neither Party may assign or transfer any rights under this Agreement or
delegate any of its obligations or duties under this Agreement (except as provided in Section
3.1) without the other Party’s prior written consent. Notwithstanding the foregoing, this
Agreement may be assigned by either Party to an Affiliate or to a third party in connection
with the transfer of all, or substantially all, of such Party’s business to which this
Agreement relates, including without limitation by way of merger, asset sale or a change in
control. Any attempted assignment or transfer of this Agreement or in violation of the
foregoing will be null and void.
	 
	9.2	 	Binding Upon Successors and Assigns. This Agreement shall be binding upon and inure
to the benefit of successors in interest and permitted assigns of STI and OPKO.

Article 10
- Confidentiality

	10.1	 	Confidential Information. As used herein, “Confidential Information” means any
confidential or proprietary information disclosed by either Party (“Disclosing Party”) to the
other Party (“Receiving Party”) pursuant to this Agreement, regardless whether such
information is marked “Confidential”. Confidential Information will include, but not be
limited to, trade secrets, know-how, inventions, unpublished patent applications, techniques,
processes, product plans, composition of matter, and financial information.
	 
	10.2	 	Confidentiality. The Receiving Party shall keep in confidence and trust all of the
Disclosing Party’s Confidential Information received by the Receiving Party. The Receiving
Party shall not use the Confidential Information of the Disclosing Party other than as
expressly permitted under the terms of this Agreement or by a separate written agreement. The
Receiving Party shall take all reasonable steps to prevent unauthorized disclosure or use of
the Disclosing Party’s Confidential Information and to prevent it from falling into the public
domain or into the possession of unauthorized persons. The Receiving Party shall not disclose
Confidential Information of the Disclosing Party to any person or entity other than its
officers, employees, consultants and advisors who need access to such Confidential Information
in order to effect the intent of this Agreement and who have entered into written
confidentiality agreements with the Receiving Party which protects the Confidential
Information of the Disclosing Party. The Receiving Party shall immediately give notice to the
Disclosing Party of any unauthorized use or disclosure of Disclosing Party’s Confidential
Information. The Receiving Party agrees to assist the Disclosing Party to remedy such
unauthorized use or disclosure of its Confidential Information.
	 
	10.3	 	Exclusions. Notwithstanding anything to the contrary herein, the restrictions set
forth in this Section shall not apply to information that the Receiving Party can document:
(i) was independently developed by the Receiving Party without any use of or reference to the
Disclosing Party’s Confidential Information; (ii) becomes known to the Receiving Party,

Page 8

 

without restriction, from a third party who had a right to disclose it without
confidentiality obligations; (iii) was in the public domain at the time it was disclosed or
becomes in the public domain without breach by the Receiving Party of this Section; or (iv)
was rightfully known to the Receiving Party, without restriction, at the time of disclosure.
A disclosure of the other Party’s Confidential Information that is required in response to
the valid and binding order of a court or other governmental body shall not be deemed a
breach of this Section; provided that the Receiving Party shall (x) immediately notify the
Disclosing Party in writing in order that the Disclosing Party may obtain a protective order
requiring the Disclosing Party’s Confidential Information be used only for which the order
was issued; and (y) use reasonable efforts to have such information be treated as
confidential and under seal, unless such disclosure is necessary to establish the rights or
enforce obligations under this Agreement.

	10.4	 	Return of Confidential Information. The Confidential Information of each Party will
remain the sole property of that Party. The disclosure of any Confidential Information by a
Party will not constitute a grant of any right or license in or to such Confidential
Information or obligate the Disclosing Party to grant any such rights or licenses to the
Receiving Party. Except as provided in this Agreement, all documents or materials that
contain or reflect Confidential Information will be returned to the Disclosing Party upon
request or termination of this Agreement; provided, however, that one (1) archival copy of
such documents or materials may be retained by the Receiving Party solely to determine its
obligations under this Agreement.
	 
	10.5	 	Terms of this Agreement. Neither Party will disclose any terms of this Agreement to
any third party without the prior written consent of the other Party, except (i) as required
by law; (ii) to its attorneys, accountants, and other professional advisors under a duty of
confidentiality; (iii) to a third party under a duty of confidentiality in connection with any
proposed financing or a proposed merger or a proposed sale of all or part of such Party’s
business relating to this Agreement.

Article 11
- General Provisions

	11.1	 	Independent Contractors. STI and OPKO shall have no other relationship other than as
independent contracting parties. Neither Party shall have any power to bind or obligate the
other Party in any manner.
	 
	11.2	 	Entire Agreement. This Agreement sets forth the entire agreement and understanding
between the Parties as to the subject matter hereof and supersedes all prior discussions,
agreements, representations related to such subject matter. There shall be no amendments or
modifications to this Agreement, except by a written document which is signed by both Parties.
	 
	11.3	 	California Law. This Agreement shall be construed and enforced in accordance with
the laws of the State of California, U.S.A., without giving effect to its principles of
conflicts of law.

Page 9

 

	11.4	 	Captions. The headings for each article and section in this Agreement are for
convenience and reference only and are not intended to limit or expand the meaning of the
language contained in the particular article or section.
	 
	11.5	 	Severability. If any provision of this Agreement is ultimately held to be invalid,
illegal or unenforceable, the validity, legality and enforceability of the remaining
provisions shall not in any way be affected or impaired thereby.
	 
	11.6	 	Notices. Any notices in writing shall be deemed duly given and made if sent by
courier or by certified or registered mail, postage prepaid, to the addressees below or by
facsimile to the facsimile number set forth below. Either Party may change its address or its
designated management representative by written notice to the other Party. The date of giving
such notices and payments shall be the date of mailing.

  To STI:

Sorrento Therapeutics, Inc.

10054 Mesa Ridge Court, Suite 122

San Diego, CA 92121

Attn: Chief Executive Officer

Fax No.: 858-481-6414

  To OPKO:

OPKO Health, Inc.

4400 Biscayne Blvd.

Miami, FL 33137

Attn: Deputy General Counsel

Fax No: 305-575-4140

	11.7	 	Remedies. If any legal action is brought to enforce this Agreement, the prevailing
Party will be entitled to receive its attorneys’ fees, court costs, and other collection
expenses, in addition to any other relief it may receive. OPKO acknowledges and agrees that
any actual or threatened breach of the license grant by OPKO will constitute immediate and
irreparable harm to STI for which monetary damages would be an inadequate remedy and that
injunctive relief is an appropriate remedy for such breach. STI acknowledges and agrees that
any actual or threatened breach of the license grant by STI will constitute immediate and
irreparable harm to OPKO for which monetary damages would be an inadequate remedy and that
injunctive relief is an appropriate remedy for such breach.
	 
	11.8	 	Counterparts and Facsimile. This Agreement may be executed in counterparts and when
each party has signed and delivered one such counterpart, each counterpart shall be deemed an
original and, when taken together with other signed counterparts, shall constitute one
integrated contract, which shall be binding upon and effective as to all parties. Facsimile
signatures and PDF copies of the parties shall have the same effect as original signatures.

[The Remainder of the Page is Left Purposely Blank]

Page 10

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed by their duly
authorized representatives as of the date first above written.

	 	 	 	 	 	 	 
	SORRENTO THERAPEUTICS, INC.	 	OPKO HEALTH, INC.
	(LICENSOR)                                               	 	(LICENSEE)                                                             
	 	 	 	 	 	 	 
	By:

	 	/s/ Antonius Schuh
	 	By:
	 	/s/ Steven Rubin
	 

	 	 
	 	 	 	 
	 

	 	Antonius Schuh	 	 	 	 
	 
	 	 	 	 	 	 
	Date:

	 	6/10/09
	 	Date:	 	 
	 

	 	 	 	 	 	 

[Signature Page to Limited License Agreement]

Page 11

 

Exhibit A

List of STI Patents

	 	 	 	 	 
	Patent/Application No.	 	Title	 	Filing Date
	United States Patent No.

7,405,062

	 	Novel Method For
Cloning Variable

 Domain
Sequences Of

Immunological Gene
Repertoire
	 	November 13, 2003
	 
	 	 	 	 
	United States Patent
Application No.
12/124,048

	 	Novel Method For
Cloning Variable 
Domain
Sequences Of

Immunological Gene
Repertoire
	 	May 20, 2008
	 
	 	 	 	 
	PCT Application No.
PCT/US02/15125

	 	Novel Method For
Cloning Variable
 Domain
Sequences Of

Immunological Gene
Repertoire
	 	May 14, 2002
	 
	 	 	 	 
	United States Provisional 

Application No:
60/290,907

	 	Novel Method For
Cloning Variable
 Domain
Sequences Of

Immunological Gene Repertoire
	 	May 14, 2001
	 
	 	 	 	 
	European Patent
Application No.
02736798.6

	 	Novel Method For
Cloning Variable
 Domain
Sequences Of

Immunological Gene
Repertoire
	 	December 12, 2003
	 
	 	 	 	 
	Canadian Patent
Application No. 2450217

	 	Novel Method For
Cloning Variable 
Domain
Sequences Of

Immunological Gene
Repertoire
	 	December 12, 2003
	 
	 	 	 	 
	Australian Patent
Application No.
2002309777

	 	Novel Method For
Cloning Variable
 Domain
Sequences Of

Immunological Gene
Repertoire
	 	December 12, 2003

Page 1exv10w10

Exhibit 10.10

*** Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4) and 17 C.F.R. 24b-2

PATENT ASSIGNMENT AGREEMENT

     This Patent Assignment Agreement (“Agreement”) is made as of June 10, 2009 by Henry H. Ji, an
individual (“Assignor”), to Sorrento Therapeutics, Inc., a California corporation having a place of
business at 10054 Mesa Ridge Court, Suite 122, San Diego, CA 92121 (“Assignee”).

     WHEREAS Assignor owns the patent(s) (“Patents”) and patent applications (“Patent
Applications”) set forth in Exhibit A hereto; and

     WHEREAS Assignee desires to acquire Assignor’s entire right, title and interest in and to the
Patents, Patent Applications, and the Future Patents (as hereinafter defined);

     NOW, THEREFORE, in consideration of mutual covenants and agreements set forth below, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

     1. Assignment of Patents and Patent Applications. Assignor hereby irrevocably and
unconditionally grants, conveys, transfers, and assigns to Assignee for the sum of [...***...] payable
in cash and, upon presentment of invoices, reimbursement of fees and costs associated with the
filing, prosecution and maintenance of the Patents (defined below), up to a maximum amount of
[...***...], all of Assignor’s right, title and interest in and to the Patents, the Patent
Applications, the inventions disclosed therein, and all future patents that may issue from Patent
Applications throughout the world, and all foreign counterparts, divisionals, continuations in
whole or in part, reexaminations, reissues, substitutions or extensions of any of the preceding
(collectively “Future Patents”), and the right to claim priority to any of the preceding, the same
to be held by Assignee for Assignee’s own use and enjoyment, and for the use and enjoyment of
Assignee’s successors, assigns and other legal representatives, as fully and entirely as the same
would have been held and enjoyed by Assignor if this Agreement had not been made; together with all
claims for damages by reason of past, present and future infringements of the Patent Applications,
Patents and Future Patents and the right to sue for and collect such damages, as permitted under
the applicable laws for any jurisdiction or country in which such claims may be asserted (provided,
however, that the foregoing does not require Assignor to pay to Assignee any revenues or damages
previously recovered or to be recovered pursuant to contracts previously concluded by Assignor, nor
does it amend any other written agreements between Assignor and Assignee with respect thereto), for
the use and benefit of Assignee and its successors, assigns and other legal representatives.

     2. Issuance of Future Patents. Assignor hereby authorizes and requests the
Commissioner of Patents and Trademarks of the United States, and any officer of any country or
countries foreign to the United States, whose duty it is to issue patents or other evidence or
forms of intellectual property protection or applications as aforesaid, to issue the Future Patents
to Assignee

*Confidential Treatment Requested

1

 

and its successors, assigns and other legal representatives in accordance with the terms of
this instrument.

     3. Assistance. Assignor shall not execute any writing or do any act whatsoever
conflicting with the terms and conditions of this Agreement, and Assignor agrees to perform,
without charge to Assignee (except as otherwise permitted herein), all acts deemed necessary or
desirable by Assignee to permit and assist Assignee in perfecting and enforcing the full benefits,
enjoyment, rights, title and interest throughout the world in all Patents, Patent Applications and
Future Patents, and the intellectual property rights therein assigned to Assignee hereunder. Such
acts may include execution of documents, including any and all powers of attorney, applications,
assignments, declarations, affidavits, and any other papers in connection therewith reasonably
necessary to perfect such benefits, enjoyment, rights, title and interest in Assignee, assistance
and cooperation in the registration and enforcement of applicable intellectual property rights or
other legal proceedings, including providing documents and materials in the possession or control
of Assignor, testifying in any legal proceedings, signing lawful papers and making all lawful oaths
at Assignee’s expense, and generally doing everything possible to aid Assignee in obtaining and
enforcing proper protection for applicable intellectual property rights, it being understood that
the foregoing covenants and agreements shall bind and inure to the benefit of the assigns and legal
representatives of Assignor and Assignee.

     4. Power of Attorney. If Assignee is unable, for any reason, to obtain the
assistance of Assignor as set forth in Section 3 above, Assignor hereby designates and appoints
Assignee as Assignor’s agent and attorney-in-fact, with full power of substitution in Assignor’s
name and stead, to act for and on behalf of Assignor to take any and all steps, including
proceedings at law, in equity or otherwise, to execute, acknowledge, verify, file and deliver any
and all instruments and assurances and to perform all other lawfully permitted acts necessary or
expedient in order to vest or perfect the aforesaid rights and causes of action more effectively in
Assignee or to protect the same or to enforce any claim or right of any kind with respect thereto
with the same legal force and effect as if executed by Assignor. Assignor hereby declares that the
foregoing power is coupled with an interest and as such is irrevocable.

     5. Delivery. Within 10 days after execution of this Agreement, Assignor shall
deliver to Assignee, for each Patent, Patent Application and Future Patent, copies of (i) the
prosecution files and all additional documents and materials relating to prosecution and, if
applicable, maintenance; (ii) all documents and materials relating to the inventions disclosed
therein (including laboratory notebooks and invention disclosure forms); and (iii) a docket listing
all actions required for the first ninety (90) days following execution of this Agreement. If the
documentation of the Patents, Patent Applications and all related intellectual property is
currently being handled by a law firm, then Assignor shall notify such law firm in writing of the
assignment and transfer to Assignee contemplated hereby.

     6. Representations and Warranties. Assignor represents and warrants that: (i)
Assignor has full right, power, and authority to enter into this Agreement and to perform its
obligations and duties under this Agreement, and that the performance of such obligations and
duties does not and will not conflict with or result in a breach of any other agreements to which
Assignor is a party or any judgment, order, or decree by which Assignor is bound; and (ii) Assignor
is the sole

2

 

and exclusive owner of all right, title, and interest in and to the Patents, Patent
Applications and Future Patents, free and clear of any security interest, option, lien, license, or
encumbrance of any nature.

     8. General.

          A. Notice. Any notice, approval, authorization, consent, or other communication
required or permitted to be delivered to either party under this Agreement must be in writing and
will be deemed properly delivered, given, and received (i) when delivered by hand, or (ii) two (2)
business days after delivered by courier or express delivery service to the address set forth
beneath the name of such party below (or to such other address or to a facsimile number as such
party may have specified in a written notice to the other party):

	 	 	 
	If to Assignor, to:

	 	If to Assignee, to:
	 
	 	 
	Henry H. Ji

	 	Sorrento Therapeutics, Inc.
	 

	 	10054 Mesa Ridge Court, Suite 122
	 

	 	San Diego, CA 92121
	 

	 	Attn: Chief Executive Officer

          B. Governing Law. This Agreement will be construed in accordance with and governed in
all respects by the laws of the State of California without reference to principles of conflict of
laws. Any legal action or other legal proceeding relating to this Agreement or the enforcement of
any provision of this Agreement may be brought or otherwise commenced in any state court located in
San Diego County, California or any federal court located in the Southern District of California.
Each party expressly and irrevocably consents and submits to the jurisdiction of each such state
and federal courts (and each appellate courts thereof).

          C. Remedies. The rights and remedies of the parties will be cumulative (and not
alternative). If any legal action is brought to enforce this Agreement, the prevailing party will
be entitled to receive its attorneys’ fees, court costs, and other collection expenses, in addition
to any other relief it may receive.

          D. Waiver. All waivers must be in writing and signed by an authorized representative
of the party to be charged. Any waiver or failure to enforce any provision of this Agreement on
one occasion will not be deemed a waiver of any other provision or of such provision on any other
occasion.

          E. Severability. If any provision of this Agreement is unenforceable, such provision
will be changed and interpreted to accomplish the objectives of such provision to the greatest
extent possible under applicable law and the remaining provisions will continue in full force and
effect.

3

 

          F. Independent Contractors. This Agreement is not intended to establish any
partnership, joint venture, employment, or other relationship between the parties except that of
independent contractors.

          G. Construction. The section headings in this Agreement are for convenience of
reference only, will not be deemed to be a part of this Agreement, and will not be referred to in
connection with the construction or interpretation of this Agreement. Any rule of construction to
the effect that ambiguities are to be resolved against the drafting party will not be applied in
the construction or interpretation of this Agreement. As used in this Agreement, the words
“include” and “including,” and variations thereof, will not be deemed to be terms of limitation,
but rather will be deemed to be followed by the words “without limitation.” All references in this
Agreement to “Sections” are intended to refer to Sections of this Agreement.

          H. Entire Agreement. This Agreement, including the Exhibit A, sets forth the entire
understanding of the parties relating to the subject matter hereof and supersedes all prior
agreements and understandings between the parties relating to the subject matter hereof. This
Agreement may not be amended, modified, altered, or supplemented other than by means of a written
instrument duly executed and delivered on behalf of both parties.

          I. Counterparts. This Agreement may be executed in several counterparts, each of
which will constitute an original and all of which, when taken together, will constitute one
agreement.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

4

 

IN WITNESS WHEREOF, the parties have executed this Agreement on the date first above written.

	 	 	 	 	 	 	 	 	 	 	 
	Assignor:	 	 	 	Assignee:	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Henry H. Ji	 	 	 	Sorrento Therapeutics, Inc.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Signature:

	 	/s/ Henry H. Ji
	 	 	 	By:
	 	/s/ Antonius Schuh	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Name: Antonius Schuh, Chief Executive Officer	 	 

[SIGNATURE PAGE TO PATENT ASSIGNMENT AGREEMENT]

5

 

Exhibit A

	 	 	 	 	 
	Patent/Application No.	 	Title	 	Filing Date
	United States Patent No.
7,405,062	 	Novel Method For
Cloning Variable
Domain Sequences Of
Immunological Gene
Repertoire	 	November 13, 2003
	 
	 	 	 	 
	United States Patent Application

No. 12/124,048	 	Novel Method For
Cloning Variable
Domain Sequences Of
Immunological Gene
Repertoire	 	May 20, 2008
	 
	 	 	 	 
	PCT Application No.
PCT/US02/15125	 	Novel Method For
Cloning Variable
Domain Sequences Of
Immunological Gene
Repertoire	 	May 14, 2002
	 
	 	 	 	 
	United States Provisional
Application 
No: 60/290,907	 	Novel Method For
Cloning Variable
Domain Sequences Of
Immunological Gene
Repertoire	 	May 14, 2001
	 
	 	 	 	 
	European Patent Application 
No.
02736798.6	 	Novel Method For
Cloning Variable
Domain Sequences Of
Immunological Gene
Repertoire	 	December 12, 2003
	 
	 	 	 	 
	Canadian Patent Application No.
2450217	 	Novel Method For
Cloning Variable
Domain Sequences Of
Immunological Gene
Repertoire	 	December 12, 2003
	 
	 	 	 	 
	Australian Patent Application 
No.
2002309777	 	Novel Method For
Cloning Variable
Domain Sequences Of
Immunological Gene
Repertoire	 	December 12, 2003

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]